Publications
5803 Results
- Journal / Conference
- JAMA Oncol. 2025 Dec 11:e255220. doi: 10.1001/jamaoncol.2025.5220. Online ahead of print.
- Year
- 2025
- Research Committee(s)
- Breast
- PMID
- PMID41379459
- PMC
- PMC12699395
- Study Number(s)
- S1007
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial
- Journal / Conference
- JCO Oncol Adv. 2025 Nov;2(1):10.1200/oa-25-00110. doi: 10.1200/oa-25-00110. Epub 2025 Nov 24.NIHMS2119227
- Year
- 2025
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID41358143
- PMC
- PMC12680016
- Study Number(s)
- S1609
Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Prior anti-PD-1/L1 Exposure (NCI/SWOG S1609)
- Journal / Conference
- J Immunother Cancer. 2025 Oct 20;13(10):e013147. doi: 10.1136/jitc-2025-013147
- Year
- 2025
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID41120126
- PMC
- PMC12542749
- Study Number(s)
- S1609
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609 (Cohort 38)
- Journal / Conference
- J Clin Oncol. 2025 Mar 10;43(8):972-984. doi: 10.1200/JCO-24-01715. Epub 2024 Dec 2.NIHMS2078704
- Year
- 2025
- Research Committee(s)
- Leukemia
- PMID
- PMID39621969
- PMC
- PMC12363388
- Study Number(s)
- S0106
Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration
- Journal / Conference
- JAMA Oncol. 2026;12;(2):185-193. 10.1001/jamaoncol.2025.5549. Epub 2025 Dec 26.
- Year
- 2025
Baseline Fatigue and Severe Toxic Effects in Patients With Cancer Receiving Systemic Therapy
- Journal / Conference
- JAMA Oncol. 2025 Dec 4:e255144. doi: 10.1001/jamaoncol.2025.5144. Online ahead of print.NIHMS2113693
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID41343176
- PMC
- PMC12679421
- Study Number(s)
- CTSU/C80702
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial
- Journal / Conference
- Bladder Cancer. 2025 Feb 24;11(1):23523735251319185. doi: 10.1177/23523735251319185. eCollection 2025 Jan-Mar.
- Year
- 2025
- Research Committee(s)
- Genitourinary
- PMID
- PMID40034245
- PMC
- PMC11863732
- Study Number(s)
- S1806
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer()
- Journal / Conference
- Prostate. 2025 Dec;85(16):1522-1530. doi: 10.1002/pros.70043. Epub 2025 Sep 9.
- Year
- 2025
- Research Committee(s)
- Genitourinary
- PMID
- PMID40926427
- Study Number(s)
- CTSU/C90203, S9921
Impact of Testosterone Recovery on Oncologic Outcomes in High-Risk, Localized Prostate Cancer
- Journal / Conference
- Clin Cancer Res. 2025 Jun 3;31(11):2196-2209. doi: 10.1158/1078-0432.CCR-24-3108
- Year
- 2025
- Research Committee(s)
- Breast
- PMID
- PMID40100138
- PMC
- PMC12130808
- Study Number(s)
- S0500
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
- Journal / Conference
- CA Cancer J Clin. 2025 May-Jun;75(3):243-267. doi: 10.3322/caac.21880. Epub 2025 Jan 22.NIHMS2049643
- Year
- 2025
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID39841128
- PMC
- PMC12061631
- Study Number(s)
- S1609